Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 3,10-dihydroxy-2-naphthacene carboxamide or derivative doai
Reexamination Certificate
2006-05-30
2006-05-30
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
3,10-dihydroxy-2-naphthacene carboxamide or derivative doai
C514S154000, C514S262100, C514S398000
Reexamination Certificate
active
07053073
ABSTRACT:
A treatment for conditions in human beings associated with either or both reactive arthritis or bursitis comprising a combination of valacyclovir hydrochloride, minocycline hydrochloride, and metronidazole.
REFERENCES:
patent: 2946801 (1960-07-01), Fields
patent: 3148212 (1964-09-01), Boothe et al.
patent: 3226436 (1965-12-01), Petisl et al.
patent: 4177796 (1979-12-01), Franco-Vila
patent: 4521411 (1985-06-01), Koloff
patent: 5523297 (1996-06-01), Pruzanski et al.
patent: 5952367 (1999-09-01), Pak
patent: 5972389 (1999-10-01), Shell et al.
patent: 6034122 (2000-03-01), Chayen
patent: 6087382 (2000-07-01), Bonner, Jr. et al.
patent: 6093414 (2000-07-01), Capelli
patent: 6197776 (2001-03-01), Bonner, Jr. et al.
patent: 6416779 (2002-07-01), D'Augustine et al.
patent: 6465473 (2002-10-01), Bonner, Jr. et al.
patent: 6765000 (2004-07-01), Bonner et al.
patent: 2002/0031558 (2002-03-01), Yoo
patent: 2002/0151519 (2002-10-01), Shepard
patent: 2003/0055022 (2003-03-01), Bonner, Jr. et al.
patent: 2005/0059640 (2005-03-01), Bonner, Jr. et al.
patent: 2005/0137181 (2005-06-01), Bonner, Jr. et al.
patent: 2005/0176690 (2005-08-01), Bonner, Jr. et al.
Astrauskiene, D., “Efficacy of empirically prescribed amoxicillin and amoxicillin+ clavulanic acid in children's reactive arthritis: a randomized trial,” Clin Exp Rheumatol. Jul.-Aug. 2003;21(4):515-21.
Ayoub et al., “Poststreptococcal Reactive Arthritis,” Curr Opin Rheumatol. Jul. 2000;12(4):306-310.
Bardin, T., “Antimicrobial Therapy in Inflammatory Joint Disease,” Rev Rhum Engl Ed. Nov. 1998;65(11):625-629.
Bardin et al., “Antibiotic Trials in Reactive Arthritis,” Rev Rhum engl Ed. 1999 Jan. 30;66(1 suppl):63S-66S.
Bell et al., “Management of sexually acquired reactive arthritis in 19 North Thames GUM clinics,” Int J STD AIDS, Mar. 2004;15(3):195-198.
Birdi et al., “Acute rheumatic feaver and poststreptococcal reactive arthritis: diagnostic and treatment practices of pediatric subspecialists in Canada,”: J Rheumatol. Jul. 2001;28(7):1681-1688.
Brandt et al., “Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial,” Arthritis Rheum. Jul. 2005;52(7):2015-2025.
Burnette et al., “Purification and Characterization of a Rat Liver Enzyme that Hydrolyzes Valaciclovir, thel-Valyl Ester Prodrug of Acyclovir,” Chem. Abs. AN#1995;673023, J. Biol. Chem., 270(26), 15827-15831,(1995).
Ceroni et al., “Risks and complications of prolonged parenteral antibiotic treatment in children with acute osteoarticular infections,” Acta Orthop Belg. Oct. 2003;69(5):400-404.
Fryden et al., “Early antibiotic treatment of reactive arthritis associated with enteric infections: clinical and serological study,” BMJ, 1990 Dec. 8;301(6764): 1299-1302.
Hopkinson, N., “Sexually-acquired reactive arthritis,” Hosp Med. Feb. 2001;62(2):83-85.
Kamphuisen et al., “Two years of penicillin prophylaxis is sufficient to prevent clinically evident carditis in poststreptocaccal reactive arthritis,” J Intern Med. Nov. 2001;250(5):449-452.
Kloppenburg et al., “Antimicrobial therapy for rheumatoid arthritis,” Baillieres Clin Rheumatol. Nov. 1995;9(4):759-769.
Kocak et al., “Poststretptococcal Reactive Arthritis: Clinical Course and Outcome in 15 Patients,” Turk J Pediatri. Apr.-Jun. 2000;42(2):101-104.
Kvien et al., “Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study,” Ann Rheum Dis. Sep. 2005;63(9):1113-1119.
Laasila et al., “Antibiotic treatment and long term prognosis of reactive arthritis,” Ann Rheum Dis. Jul. 2003;62(7):655-658.
Lehman et al., “Clinical trials for post-streptococcal reactive arthritis,” Curr Rheumamtol Rep. Oct. 2001;3(5):363-364.
Leirisalo-Repo, M., “Therapeutic aspects of spondyhloarthropathies - - a review,” Scand J Rheumatol. 1998;27(5):323-328.
Loffler et al, “Clostridium difficile-associated reactive arthritis in two children,” Joint Bone Spine. Jan. 2004;71(1):60-62.
Morfin Maciel et al., “Reactive polyarthritis and painful dermatographism caused by Helicobacter pylori,” Rev Alerg Mex. May-Jun. 2002;49(3):99-102. Article in Spanish; abstract only is provided in English.
Neumayr et al., “Chronic reactive arthritis associated with Calmette-Guerin bacillus,” Dtsch Med Wochenschr. Sep. 13, 2002;127(37):1886-1888. Article in German; abstract only is provided in English.
Palazzi et al., “Reactive arthritis: advances in diagnosis and treatment,” Reumatismo. Apr.-Jun. 2002;54(2):105-112. Article in Italian; abstract only is provided in English.
Palazzi et al., “Management of reactive arthritis,” Expert Opin Pharmacother. Jan. 2004;5(1):61-70.
Pappas et al., “Unusual causes of reactive arthritis: Leptospira and Coxiella burnetii,” Clin Rheumatol. Oct. 2003;22(4-5):343-346.
Pott et al. letter, “Long-term antibiotic treatment in reactive arthritis,” Lancet. Jan.30, 1988;1(8579):245-246.
Shulman et al., “Poststreptococcal reactive arthritis.” Curr Opin Rheumatol. Sep.2000;14(5);562-565.
Sieper et al., “Report on the Fourth International Workshop on Reactive Arthritis,” Apr. 2000; Arhritis Rheum. Apr. 2000;43(4):720-734.
Sieper, J., “Reactive arthritis: practical procedure in diagnosis and problematic aspects of antibiotic therapy,” Z Rheumatol. Apr. 2003;62(2):110-111. Article in German; abstract only is provided in English.
Sieper et al., “No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study,” Arthritis Rheum. Jul. 1999;42(7):11386-11396.
Sieper et al., “Expert Witness Reports in Rheumatology,” British Society for Rheumatology, 1998;37:715-720.
Smieja et al., “Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis,” Ann Rheum Dis. Dec. 2001;60(12):1088-1094.
Svenungsson, B., “Reactive arthritis,” Int J STD AIDS. May-Jun. 1995;6(3):156-160.
Toivanen et al., “Reactive Arthritis,” Curr Opin Rheumatol. Jul. 1997;9(4):321-327.
Toivanen et al., “Effect of antimicrobial treatment on chronic reactive arthritis,” Clin Exp Rheumatol. May-Jun. 1993;11(3):301-307.
Toivanen et al., “Reactive arthritis,” Best Practice & Research Clinical Rheumatology, Oct. 2004;18(5):689-703.
Toivanen, A., “Bacteria-Triggered reactive arthritis: implications for antibacterial treatment,” Drugs. 2001;61(3):343-351.
Zhang et al., “Experimental Yersinia-triggered reactive arthritis: effect of a 3-week course of ciprofloxacin,” Br J Rheumatol. May 1997;36(5):541-546.
Bonner, Jr. Ernest L.
Hines Robert
Ficaar, Inc.
Henley III Raymond J.
Robins & Pasternak LLP
LandOfFree
Treatment for reactive arthritis or bursitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for reactive arthritis or bursitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for reactive arthritis or bursitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3610353